Contact us

If you have any questions,
or wish to have an appointment


Call us: 0800 0 276 276 
Mon - Fri: 8am - 6pm
Sat: 8am - 4pm
(Free from most phones)

Improving the health of future generations

3
4
7
9
9
Participants scanned so far - help us make it to 100,000! Get in touch

The UK Biobank Imaging Study aims to conduct detailed MRI imaging scans of the vital organs of over 100,000 participants, making it the largest of its kind in the world. 

Together with the information we have already collected from our participants, these images will help to improve the diagnosis and treatment of a wide range of diseases.

Take a look at the videos on this site to find out more about the imaging study. All video transcripts are available in the 'Further documents' section.

About

Hear from participants on how they found their scanning visit and why they would recommend it to a friend!
The UK Biobank imaging study is the largest of its kind in the world, scanning the hearts, brains and bodies of 100,000 participants. Take a virtual tour of the centre in the video below.
Watch this video to hear from expert imaging researchers on how unique and transformative the UK Biobank resource is for health research.
See what the BBC’s Medical Correspondent, Fergus Walsh, had to say when he became the first participant to be scanned
Hear from participants on how they found their scanning visit and why they would recommend it to a friend!
The UK Biobank imaging study is the largest of its kind in the world, scanning the hearts, brains and bodies of 100,000 participants. Take a virtual tour of the centre in the video below.
Watch this video to hear from expert imaging researchers on how unique and transformative the UK Biobank resource is for health research.
See what the BBC’s Medical Correspondent, Fergus Walsh, had to say when he became the first participant to be scanned

Further information

Now hear from our experts.

Find out what the imaging visit is like.
More information about who can be scanned and how to make an appointment
Introduction
Consent
Feedback
Eligibility
Assessment
  • Introduction
  • Consent
  • Feedback
  • Eligibility
  • Assessment
Transcripts
Heart & abdomen
Brain
Bone
Carotid artery
Transcripts

Imaging

The UK Biobank Imaging Study is one of the most ambitious and exciting health research opportunities in recent years. It will provide an unprecedented level of information to help scientists and doctors working on a wide range of illnesses.

Get in touch

Incidental findings

Abnormalities can show up on scans taken for research during the scanning process. Most of these are no cause for concern. But, if the radiographer does happen to notice a potentially serious abnormality while taking the scans, they will refer the scans after your visit to a specialist doctor (radiologist) for review. If the radiologist agrees that the abnormality is potentially serious we will write to you and your GP to tell you.

Testimonials

“Lovely staff and a pleasant environment, which made everything very easy to do and understand.”
“The staff were all wonderful and put me at ease immediately when I arrived at the centre. Nothing was too much trouble and I felt that I had arrived at a second home."
“Fascinating day - and have been very happy to help.”
"Everybody was extremely professional and proficient in their duties and a credit to the organisation.”

News

heart
Paving the way to better treatments for atrial fibrillation

During the UK Biobank imaging assessment we ask participants aged over 60 if they will wear a heart monitor for two weeks. This is to measure the occurrence of atrial fibrillation, a common heart disorder that increases the risks for blood clots, heart failure and stroke, all of which could be fatal. Scientists have already used some of this data along with information from other studies to pinpoint 150 genes linked to this disorder – paving the way for better treatments. By detecting atrial fibrillation in its early stages, it could be possible to avoid severe consequences including stroke and heart failure.

You can see read published papers using imaging data on the main UK Biobank website: published papers

View more details on the heart monitor we may ask some participants to wear here: heart monitor

 

View Article
hqdefault
 25,000 participants scanned in the UK Biobank imaging study

26 Nov 2018

Thank you to all the participants who have attended an imaging visit so far. If you would like to find out more about the UK Biobank Imaging Study please visit the imaging website:

https://imaging.ukbiobank.ac.uk/

Imaging researchers react to this milestone:

This globally important resource permits a unique opportunity for world-leading multidisciplinary discovery science, uniquely facilitating analyses across multiple organ systems, combining detailed mechanistic information with the comprehensive imaging, and places the UK at the forefront of biomedical science internationally.

Professor Nick Harvey, Southampton University

It already is 5x larger than the largest population research imaging study conducted anywhere in the world to date.  Such size is essential for gaining sufficient sensitivity to make out the “signatures” of diseases that affect the older UK population well before they happen, when they still can be prevented.

Paul M. Matthews, OBE, MD, DPhil, FRCP, FMedSci

Edmond and Lily Safra Chair,  Division of Brain Sciences, Associate Director, UK Dementia Research Institute

Imperial College London

In the first 25,000 UK Biobank imaging participants, we’ll have scanned 500 people who go on to receive a diagnosis of Alzheimer’s by 2022. This will enable us to identify the signatures of dementia in the brain before individuals begin to get sick.

Professor Karla Miller, FMRIB

View Article
2
Imaging Study Reveals Potential Biomarker for Liver Health in Metabolic Diseases

26 Nov 2018

An MRI-based measure, corrected T1 (cT1), could be used as a potential biomarker for liver health, a study in collaboration with Massachusetts General Hospital, Perspectum Diagnostics and the University of Westminster has found.

This image shows a patient with cT1 in the normal range and low liver fat. This has been quantified using LiverMultiScan.  

This study involved over 2,800 subjects from the UK BioBank MRI imaging study. The paper has revealed a tight distribution of cT1 values in a sub-population at low risk for non-alcoholic fatty liver disease. In comparison, the cT1 values were significantly elevated in 'higher-risk' sub-populations.

With the burgeoning obesity epidemic, the prevalence of both Non-Alcoholic Fatty Liver Disease (NAFLD), the build-up of fat in the liver, and Non-Alcoholic Steatohepatitis (NASH) inflammation in the liver, are rapidly increasing. Liver disease, including NAFLD and NASH, is usually asymptomatic until the development of cirrhosis, therefore it is critical to identify individuals who are risk and enable early diagnosis. In order to establish which populations are at risk, normality and abnormality need to be ascertained in the context of NAFL and NASH.

Of the population studied, only 37% of participants were classified as being at 'low risk' of NAFLD, i.e. those with a BMI under 25kg/m2and liver fat under 5%. Perspectum Diagnostics' proprietary technology, LiverMultiScan™ was used to calculate the patients' cT1 values. In separate research studies this novel imaging biomarker has been shown to correlate with histology and to predict prognosis (Banerjee, 2014; Pavlides, 2016). The results in this paper showed a tight distribution in the low-risk group, which can act as a baseline comparator in the diagnosis of patients with suspected NAFLD and NASH. The excellent intra-rater and inter-rater reproducibility observed in this study for cT1 provides further support for its utility. Separate research (Pavlides, 2017) has shown that cT1 can distinguish between NAFL and NASH, increasing its utility and adding value to a fat content measure alone to assess fatty liver disease.

Professor Stefan Neubauer, Chief Medical Officer at Perspectum Diagnostics, commented that, "Currently patients with suspected liver disease are biopsied which can cause great pain and distress, and there is a big need for a non-invasive biomarker to enable better care of patients. This study establishes a tight normal range for cT1 in a large low-risk population, an important pre-requisite for an imaging biomarker that can an aid early diagnosis and, hopefully, will reduce the number of patients who are unnecessarily biopsied."

LiverMultiScan corrects for the amount of iron in the liver, as high iron levels can distort the magnetic field and obscure the readings. In this population 36.5% of subjects had sufficiently high iron concentration in their livers to necessitate correction, emphasizing the importance of this method. Iron correction was also needed in cases of mild iron overload that in itself does not pose a clinical problem.

This paper includes an appendix of interesting case studies taken from the Patient Understanding of LiverMultiScan trial and from Massachusetts General Hospital, these case studies show the use of LiverMultiScan and cT1 across a variety of diseases. Dr Amirkasra Mojtahed from the Division of Abdominal Imaging at Massachusetts General Hospital, Boston stated that, "As we move into the era of personalized medicine, it is increasingly becoming important to develop quantitative imaging biomarkers that are uniform across various vendor platforms. This study is an important step in the path for developing a standardized imaging biomarker for liver health and has the potential to replace some of the inherently subjective current methods of assessing liver health."

This manuscript adds to the growing literature on T1 mapping in the liver and displays, for the first time, the reference range of cT1 values in a large population at low risk for NAFL, therefore demonstrating its potential as a biomarker for future studies.

Read the published paper:

Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases

View Article
exhaust 3538388 1920
New research links even low levels of air pollution with serious changes in the heart

26 Nov 2018

Researchers have found that people exposed to air pollution levels well within UK guidelines have changes in the structure of the heart, similar to those seen in the early stages of heart failure. The research was part-funded by the British Heart Foundation (BHF) and is published in the journal Circulation. [1]

A team of scientists, led from Queen Mary University of London by Professor Steffen Petersen, studied data from around 4,000 participants in the UK Biobank study. Researchers accessed information provided on their lifestyles, health records and details on where they have lived, so the research team were able to remove patients with underlying heart problems, or those who had moved house during the study. Heart MRI (magnetic resonance imaging) was used to measure the size, weight and function of the participants’ hearts at fixed times. [2]

Even though most participants lived outside major UK cities, there was a clear association between those who lived near loud, busy roads, and were exposed to nitrogen dioxide (NO2) or PM2.5 - small particles of air pollution – and the development of larger right and left ventricles in the heart. The ventricles are important pumping chambers in the heart and, although these participants were healthy and had no symptoms, similar heart remodelling is seen in the early stages of heart failure.

Higher exposures to the pollutants were linked to more significant changes in the structure of the heart. For every 1 extra µg per cubic metre of PM2.5 and for every 10 extra µg per cubic metre of NO2, the heart enlarges by approximately 1%.

Air pollution is now the largest environmental risk factor linked to deaths in England. Globally, coronary heart disease and stroke account for approximately six in ten (58%) deaths related to outdoor air pollution. This research could help explain exactly how and why air pollution affects the heart.

In the study, average annual exposures to PM2.5 (8-12µg per cubic metre) were well within UK guidelines (25µg per cubic metre), although they were approaching or past World Health Organisation (WHO) guidelines (10µg per cubic metre). The WHO has said that there are no safe limits of PM2.5. The participants’ average exposure to NO2 (10-50µg per cubic metre) was approaching and above the equal WHO and UK annual average guidelines (40µg per cubic metre).

Dr Nay Aung who led the data analysis from Queen Mary University of London said: “Although our study was observational and hasn’t yet shown a causal link, we saw significant changes in the heart, even at relatively low levels of air pollution exposure. Our future studies will include data from those living in inner cities like Central Manchester and London, using more in-depth measurements of heart function, and we would expect the findings to be even more pronounced and clinically important.

“Air pollution should be seen as a modifiable risk factor. Doctors and the general public all need to be aware of the their exposure when they think about their heart health, just like they think about their blood pressure, their cholesterol and their weight.”

Mya Steer, 19, lives just outside Bristol, she was diagnosed with an inherited heart condition, arrhythmogenic right ventricular cardiomyopathy (ARVC) just after her 18th birthday:  “My heart condition means that I often struggle to breathe anyway and air pollution makes me feel much worse – it’s pretty instant. This research just goes to show that pollution is affecting us all, whether we live in busy cities or more rural areas where we might feel ‘protected’ from pollution.

“There is no safe limit for air pollution for me, or for anyone who is concerned about their heart health – we all need the Government to do more.”

Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation, which part-funded the study said: “We can’t expect people to move home to avoid air pollution – Government and public bodies must be acting right now to make all areas safe and protect the population from these harms.

“What is particularly worrying is that the levels of air pollution, particularly PM2.5, at which this study saw people with heart remodelling are not even deemed particularly high by the UK Government – this is why we are calling for the WHO guidelines to be adopted. They are less than half of UK legal limits and while we know there are no safe limits for some forms of air pollution, we believe this is a crucial step in protecting the nation’s heart health.

“Having these targets in law will also help to improve the lives of those currently living with heart and circulatory diseases, as we know they are particularly affected by air pollution.”

This research was a collaboration between Queen Mary University of London and the University of Oxford. 

1. Association between ambient air pollution and cardiac morpho-functional phenotypes: Insights from the UK Biobank population imaging study, Aung et al.

2. Ejection fraction is used as a measure of heart function 

View Article

How to find us:

If you would like to speak to someone, please call our free phone Participant Resource Centre on 0800 0 276 276, 8am-6pm Monday to Friday and 8am-4pm on Saturday.

You should call the PRC if you wish to confirm or change your appointment, or update your contact details.

You can email us: ukbiobank@ukbiobank.ac.uk

Travel Expenses

If you are travelling to an appointment you can claim reasonable expenses (25p/mile for a car). If coming by train, it would really help us if you could consider booking your ticket in advance, to get the best value for money.

You can book online and pick up your tickets at the station. You can buy "split tickets" that may reduce the overall price you pay. Visit the website: splitticketing.com to find out more. Money saved will help us create a better resource for research.

Feedback sent successfully
Close
Form sent successfully
Close